Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study

Abstract

Abstract Busulfan (Bu) is commonly used in myeloablative conditioning regimens for children undergoing hematopoietic stem cell transplantation. The standard target area under the concentration-time curve (AUC) of Bu is approximately 900–1500\u2009µM\u2009min. In previous studies using five fixed doses (0.8–1.2\u2009mg/kg) for Bu without dose adjustment, 75% patients achieved the target AUC. The aim of this pilot study was to determine the percentage of target AUC for intravenous (IV) Bu in Thai children. IV Bu was administered every 6\u2009h over 16 doses. Blood samples were collected for pharmacokinetic (PK) analysis after the first, ninth, and thirteenth doses of Bu. Seven patients (2–14\u2009years; median 6\u2009years) were diagnosed with thalassemia (n\u2009=\u20094), acute myeloid leukemia (n\u2009=\u20092), and pure red cell aplasia. Three, two, and two patients received Bu at 1.1, 1.2, and 0.8\u2009mg/kg, respectively. The AUC of Bu varied from 292–1714\u2009µM\u2009min (median = 804). Nine (42.86%), eleven (52.38%), and one (4.76%) AUC values were within, below, and above the target, respectively. The median (range) Bu clearance was 5.93 (1.91–14.65) mL/min/kg. In this study, 42.86% AUC value achieved the target, which was lower than that in previous studies. Therapeutic drug monitoring (TDM) of Bu should be considered in Thai children receiving five fixed doses of IV Bu, and dose adjustment should be performed as necessary. Further PK studies for Bu with a larger sample size are warranted for confirming the necessity of TDM in every step dose of Bu. (Trial registration numbers; TCTR20190528003)